QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
NASDAQ:SNGX

Soligenix - SNGX Stock Forecast, Price & News

$0.87
+0.01 (+1.16%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.84
▼
$0.89
50-Day Range
$0.51
▼
$0.94
52-Week Range
$0.38
▼
$1.23
Volume
93,630 shs
Average Volume
284,515 shs
Market Capitalization
$37.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.75

Soligenix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
331.0% Upside
$3.75 Price Target
Short Interest
Healthy
0.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$12,800 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.32) to ($0.34) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

486th out of 1,112 stocks

Pharmaceutical Preparations Industry

233rd out of 544 stocks

See Top Rated MarketRank™ Stocks Here
SNGX stock logo

About Soligenix (NASDAQ:SNGX) Stock

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Soligenix Trading Up 1.2 %

SNGX opened at $0.86 on Thursday. Soligenix has a twelve month low of $0.38 and a twelve month high of $1.23. The company has a 50-day simple moving average of $0.68 and a 200 day simple moving average of $0.65. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 1.50.

Soligenix (NASDAQ:SNGX - Get Rating) last issued its earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative return on equity of 121.28% and a negative net margin of 1,710.71%. On average, research analysts predict that Soligenix will post -0.32 earnings per share for the current fiscal year.

Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Stock News Headlines

August 4, 2022 | americanbankingnews.com
Soligenix, Inc. (NASDAQ:SNGX) Short Interest Update
July 27, 2022 | uk.investing.com
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy By Benzinga - Investing.com UK
July 27, 2022 | finance.yahoo.com
Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
July 26, 2022 | finance.yahoo.com
Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients - Yahoo Finance
July 26, 2022 | streetinsider.com
Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients - StreetInsider.com
July 26, 2022 | finance.yahoo.com
Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients
July 25, 2022 | finance.yahoo.com
Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines - Yahoo Finance
July 25, 2022 | benzinga.com
Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix - Benzinga
July 25, 2022 | finance.yahoo.com
Soligenix Partners With SERB Pharmaceuticals To Supply Ricin Antigen For Ricin Toxin Poisoning Treatment
July 25, 2022 | finance.yahoo.com
Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen
July 20, 2022 | nasdaq.com
Health Care Sector Update for 07/20/2022: VBLT, NVAX, SNGX - Nasdaq
July 20, 2022 | benzinga.com
Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study - Benzinga - Benzinga
July 20, 2022 | finance.yahoo.com
Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study
July 20, 2022 | benzinga.com
Soligenix shares are trading higher after the company announced results of its Phase 3 FLASH study evalua - Benzinga
July 20, 2022 | streetinsider.com
Soligenix (SNGX) Announces Publication of HyBryte Phase 3 FLASH Study for Treatment of Cutaneous T-Cell Lymphoma - StreetInsider.com
July 20, 2022 | finance.yahoo.com
HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology
July 15, 2022 | finance.yahoo.com
Global Cutaneous T-cell Lymphoma (CTCL) Treatment Market to be Driven by Rising Prevalence of Lymphoma Cancer and Growing Advances in Cancer Treatment at a CAGR of ~5% over 2022-2030 - Yahoo Finance
July 14, 2022 | globenewswire.com
SERB Pharmaceuticals licenses Soligenix antigen to develop ricin antidote - GlobeNewswire
July 6, 2022 | finance.yahoo.com
Oral Mucositis Market to Surge at a Considerable CAGR During the Study Period (2019-2032) | DelveInsight - Yahoo Finance
June 28, 2022 | finance.yahoo.com
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis - Yahoo Finance
June 28, 2022 | finance.yahoo.com
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
June 27, 2022 | benzinga.com
Zacks Small-Cap Research Issues Note On Soligenix With $4 Valuation - Benzinga - Benzinga
June 23, 2022 | nasdaq.com
Wall Street Might Bounce Back; All Eyes On Powell's Testimony - Nasdaq
June 23, 2022 | finance.yahoo.com
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine - Yahoo Finance
June 7, 2022 | finance.yahoo.com
Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis
See More Headlines
Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Company Calendar

Last Earnings
5/13/2022
Today
8/11/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNGX
CUSIP
N/A
CIK
812796
Web
www.soligenix.com
Phone
(609) 538-8200
Fax
609-452-6467
Employees
13
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$3.75
High Stock Price Forecast
$3.75
Low Stock Price Forecast
$3.75
Forecasted Upside/Downside
+331.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-13,420,000.00
Net Margins
-1,710.71%
Pretax Margin
-1,812.12%
Return on Equity
-121.28%
Return on Assets
-52.94%

Debt

Debt-to-Equity Ratio
1.50
Current Ratio
3.25
Quick Ratio
3.25

Sales & Book Value

Annual Sales
$820,000.00
Price / Sales
45.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.27 per share
Price / Book
3.22

Miscellaneous

Outstanding Shares
43,050,000
Free Float
41,810,000
Market Cap
$37.45 million
Optionable
Not Optionable
Beta
1.35

Social Links


Key Executives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SNGX Stock - Frequently Asked Questions

Should I buy or sell Soligenix stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNGX shares.
View SNGX analyst ratings or view top-rated stocks.

What is Soligenix's stock price forecast for 2022?

1 analysts have issued 1 year target prices for Soligenix's shares. Their SNGX share price forecasts range from $3.75 to $3.75. On average, they anticipate the company's stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 334.3% from the stock's current price.
View analysts price targets for SNGX or view top-rated stocks among Wall Street analysts.

How have SNGX shares performed in 2022?

Soligenix's stock was trading at $0.66 at the beginning of the year. Since then, SNGX stock has increased by 30.8% and is now trading at $0.8634.
View the best growth stocks for 2022 here.

Are investors shorting Soligenix?

Soligenix saw a decrease in short interest in July. As of July 31st, there was short interest totaling 316,200 shares, a decrease of 34.1% from the July 15th total of 479,800 shares. Based on an average trading volume of 220,400 shares, the days-to-cover ratio is currently 1.4 days.
View Soligenix's Short Interest.

When is Soligenix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our SNGX earnings forecast.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) posted its quarterly earnings data on Friday, May, 13th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.04. The biopharmaceutical company earned $0.19 million during the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative net margin of 1,710.71% and a negative trailing twelve-month return on equity of 121.28%.

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

How do I buy shares of Soligenix?

Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $0.86.

How much money does Soligenix make?

Soligenix (NASDAQ:SNGX) has a market capitalization of $37.17 million and generates $820,000.00 in revenue each year. The biopharmaceutical company earns $-13,420,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

When was Soligenix founded?

Soligenix was founded in 1987.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The official website for the company is www.soligenix.com. The biopharmaceutical company can be reached via phone at (609) 538-8200, via email at ir@soligenix.com, or via fax at 609-452-6467.

This page (NASDAQ:SNGX) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.